Psychedelic Experiences
15
2
3
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.7%
1 terminated out of 15 trials
85.7%
-0.9% vs benchmark
0%
0 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (15)
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (Quantum AI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360)
Psychedelic Virtual Reality
Safety for Home Administration of Microdose Psilocybin Use
The ENHANCE Study: taVNS and Psilocybin
Neural and Physiological Correlates of Psychedelic Sub-states
Antidepressant Response of DMT Masked With Propofol
Visual Surround Suppression and Perceptual Expectation Under Psilocybin
Consciousness, Psilocybin, and Well-Being
The Effects of Psilocybin on Shared Experience in Film Processing
Pilot RECAP Study in Healthy Volunteers
Mood and Cognitive Effects of Psilocybin in Healthy Participants
Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids
Ketamine Therapy Experiential Education Study
Entheogen Resurgence